Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
NEJM Evidence
|
February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers
Michael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Science Translational Medicine
|
March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma
Bart Burington, Peng Yue, Xiaoyan Shi, et al.
Cancer Discovery
|
November 23, 2022
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Sarah M Larson, Christopher M Walthers, Brenda Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
Bertrand Coiffier, Weimin Li, Erin D Henitz, et al.
Nature Medicine
|
June 3, 2024
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Franck Morschhauser, Saurabh Dahiya, M Lia Palomba, et al.
Nature Medicine
|
July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
The New England Journal of Medicine
|
June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
John C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 15, 2021
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Andrew D Zelenetz, Leo I Gordon, Julie E Chang, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
NEJM Evidence
|
February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers
Michael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Science Translational Medicine
|
March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma
Bart Burington, Peng Yue, Xiaoyan Shi, et al.
Cancer Discovery
|
November 23, 2022
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Sarah M Larson, Christopher M Walthers, Brenda Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
Bertrand Coiffier, Weimin Li, Erin D Henitz, et al.
Nature Medicine
|
June 3, 2024
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Franck Morschhauser, Saurabh Dahiya, M Lia Palomba, et al.
Nature Medicine
|
July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
The New England Journal of Medicine
|
June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
John C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 15, 2021
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Andrew D Zelenetz, Leo I Gordon, Julie E Chang, et al.
Page
of 7